Kennedy Capital Management LLC Trims Stock Position in OptimizeRx Co. (NASDAQ:OPRX)

Kennedy Capital Management LLC cut its stake in OptimizeRx Co. (NASDAQ:OPRX) by 34.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 319,799 shares of the company’s stock after selling 170,886 shares during the period. Kennedy Capital Management LLC owned about 1.76% of OptimizeRx worth $3,886,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. First Light Asset Management LLC raised its holdings in shares of OptimizeRx by 0.6% in the first quarter. First Light Asset Management LLC now owns 1,737,584 shares of the company’s stock valued at $21,112,000 after buying an additional 10,286 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of OptimizeRx by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock valued at $12,482,000 after buying an additional 6,291 shares during the last quarter. Blair William & Co. IL raised its holdings in shares of OptimizeRx by 5.6% in the first quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock valued at $9,508,000 after buying an additional 41,469 shares during the last quarter. G2 Investment Partners Management LLC raised its holdings in shares of OptimizeRx by 26.0% in the fourth quarter. G2 Investment Partners Management LLC now owns 468,120 shares of the company’s stock valued at $6,699,000 after buying an additional 96,646 shares during the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in shares of OptimizeRx by 17.3% in the first quarter. Rice Hall James & Associates LLC now owns 401,882 shares of the company’s stock valued at $4,883,000 after buying an additional 59,141 shares during the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Trading Down 1.4 %

Shares of OPRX traded down $0.16 on Tuesday, hitting $11.07. 83,132 shares of the stock traded hands, compared to its average volume of 128,719. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.88 and a current ratio of 2.88. The stock’s 50 day moving average is $10.92 and its two-hundred day moving average is $12.29. OptimizeRx Co. has a 1 year low of $6.92 and a 1 year high of $16.65.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $19.69 million for the quarter, compared to analysts’ expectations of $18.66 million. OptimizeRx had a negative net margin of 23.10% and a negative return on equity of 6.96%. During the same period in the previous year, the company posted ($0.34) EPS. On average, research analysts predict that OptimizeRx Co. will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. JMP Securities reiterated a “market outperform” rating and set a $16.00 price target on shares of OptimizeRx in a research note on Friday, June 21st. B. Riley started coverage on shares of OptimizeRx in a research note on Thursday, July 25th. They set a “buy” rating and a $18.50 price target on the stock. Stifel Nicolaus restated a “buy” rating and set a $13.00 target price on shares of OptimizeRx in a research report on Wednesday, May 15th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.07.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.